H.C. Wainwright assumed coverage of MannKind (MNKD) with a Buy rating and $9 price target The firm views the company’s pipeline as largely overlooked at current share levels. MannKind’s valuation does not balance the potential headwinds with potential tailwinds on the Tyvaso royalty, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind’s Afrezza: A Promising Undervalued Opportunity in Diabetes Treatment
- MannKind’s Growth Potential and Strategic Positioning Amidst Near-Term Uncertainties: A Buy Rating by Faisal Khurshid
- MannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical Data
- MannKind’s Strategic Growth Potential and Market Positioning: A Buy Recommendation
- MannKind Stockholders Approve Board and Compensation